|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:FOLFIRINOX
|
|
gptkbp:activities
|
DNA cross-linking agent
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2002
gptkb:Australia
gptkb:FDA
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
Eloxatin
|
|
gptkbp:can_be_used_with
|
gptkb:5-fluorouracil
gptkb:leucovorin
|
|
gptkbp:class
|
platinum compound
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:composed_of
|
ligand exchange reactions
complexation with amines
reacting oxalate with platinum
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to oxaliplatin
|
|
gptkbp:discovered_by
|
gptkb:Sanofi
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxaliplatin
|
|
gptkbp:ingredients
|
C8 H14 N2 O4 P
|
|
gptkbp:invention
|
EP Patent 0 505 200
US Patent 5,360,800
|
|
gptkbp:is_used_for
|
treatment of colorectal cancer
|
|
gptkbp:lifespan
|
about 1.5 hours
|
|
gptkbp:marketed_as
|
Eloxatin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:project
|
clinical trials
|
|
gptkbp:provides_information_on
|
FOLFOX
XELOX
|
|
gptkbp:related_to
|
platinum-based drugs
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
oncology
chemotherapy
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
vomiting
diarrhea
constipation
peripheral neuropathy
thrombocytopenia
neuropathy
stomatitis
myelosuppression
|
|
gptkbp:targets
|
gptkb:DJ
|
|
gptkbp:type_of
|
61825-94-3
|